突变的p53利用增强剂来提高免疫抑制化学激素表达,并降低胰腺癌中的免疫检查点抑制剂
Dig B Mahat1, Heena Kumra2, Sarah A Castro1
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
bioRxiv : the preprint server for biology
|September 11, 2024
概括
一种常见的胰腺癌突变 (p53R172H) 创造了一个免疫抑制的瘤微环境,阻碍了癌症治疗. 这通过增加Cxcl1化学激素表达来发生,这促进了瘤生长,并降低了免疫检查点抑制剂的有效性.
科学领域:
- 在瘤学瘤学.
- 癌症免疫学 癌症免疫学
- 分子生物学分子生物学
背景情况:
- 胰腺管道腺癌 (PDAC) 是一种具有有限治疗选择的侵袭性癌症.
- 激活KRAS突变和p53改变在PDAC中很常见.
- 这些突变对瘤微环境 (TME) 和免疫反应的影响尚未完全理解.
研究的目的:
- 研究p53R172H突变如何影响胰腺癌中的瘤微环境 (TME).
- 确定p53R172H影响瘤生长和对免疫检查点抑制剂 (ICI) 的反应的机制.
主要方法:
- 在PDAC模型中分析p53R172H对TME和ICI疗效的影响.
- 作为p53R172H功能的调解者,对Cxcl1化学激素上调的研究.
- 关于p53R172H与Cxcl1基因增强剂的相互作用的机制研究,涉及NF-κB通路.
主要成果:
- 在p53R172H突变建立了一个免疫抑制的TME,促进瘤生长.
- p53 R172H 降低了免疫检查点抑制剂 (ICI) 的有效性.
- 免疫抑制化学基因Cxcl1的上调调节调解了这些亲瘤效应,由p53R172H以NF-κB依赖的方式与Cxcl1增强剂结合驱动.
结论:
- 这种p53R172H突变劫持了增强剂活性,以增加Cxcl1的表达.
- 这导致一种免疫抑制性TME,损害了PDAC中的ICI疗效.
- 针对这种机制可以为胰腺癌提供新的治疗策略.
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:19Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K